Basilea Pharmaceutica Ltd. Logo

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

Thursday, August 21. 2014
Basel, Switzerland, August 21, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announces today that the European Medicines Agency (EMA) has accepted its isavuconazole Marketing Authorization Application (MAA) for review. Basilea's MAA seeks approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis (zygomycosis) in adults.
Monday, August 18. 2014
Basel, Switzerland, August 18, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that it has appointed David Veitch as Chief Commercial Officer of Basilea Pharmaceutica International Ltd. Mr Veitch will join the company on September 1, 2014. As a member of the management committee, he will be responsible for leading Basilea's commercial operations, including sales, marketing, pricing and market access, reporting to Chief Executive Officer Ronald Scott.
Thursday, August 14. 2014
  • Solid operational and financial performance
  • Basilea submitted isavuconazole European MAA and Astellas Pharma Inc. submitted U.S. NDA
  • Full rights to isavuconazole obtained outside U.S. and Canada
  • Cash and short-term investments of CHF 246 million
Monday, July 21. 2014
Basel, Switzerland, July 21, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that it has entered into an agreement with Quintiles (NYSE: Q) for the commercialization of Zevtera®/Mabelio® (ceftobiprole medocaril) in Europe.

Infectious Diseases
Society of America